Centessa Pharmaceuticals plc (NASDAQ:CNTA) CTO Tia L. Bush Sells 11,000 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CTO Tia L. Bush sold 11,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $16.86, for a total value of $185,460.00. Following the completion of the sale, the chief technology officer now directly owns 121,503 shares of the company's stock, valued at approximately $2,048,540.58. This represents a 8.30 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Centessa Pharmaceuticals Trading Up 6.7 %

Shares of NASDAQ:CNTA traded up $1.19 during mid-day trading on Friday, reaching $19.03. 1,506,964 shares of the company were exchanged, compared to its average volume of 556,728. Centessa Pharmaceuticals plc has a 1 year low of $7.38 and a 1 year high of $19.09. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The firm's 50-day simple moving average is $16.77 and its 200 day simple moving average is $15.40. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of -12.44 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.05. Equities research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Institutional Trading of Centessa Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. grew its stake in Centessa Pharmaceuticals by 39.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock worth $317,000 after purchasing an additional 5,316 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock valued at $64,000 after buying an additional 865 shares during the period. JPMorgan Chase & Co. grew its position in shares of Centessa Pharmaceuticals by 1,969.2% during the third quarter. JPMorgan Chase & Co. now owns 135,903 shares of the company's stock worth $2,173,000 after buying an additional 129,335 shares in the last quarter. Lord Abbett & CO. LLC purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth approximately $4,305,000. Finally, Franklin Resources Inc. raised its holdings in Centessa Pharmaceuticals by 99.1% in the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company's stock valued at $38,360,000 after acquiring an additional 1,145,823 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company's stock.

Analyst Upgrades and Downgrades

CNTA has been the subject of a number of analyst reports. Guggenheim upped their price objective on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a report on Friday, November 15th. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.